New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92
Sep 18, 2024 · 17% of patients treated with BRIUMVI continuously for 5 years achieved Confirmed Disability Improvement (CDI) lasting at least 24 weeks compared to 12.2% of patients who switched from teriflunomide to BRIUMVI [HR (95% CI): 1.472 (1.048, 2.067); p=0.0249], resulting in one in six patients experiencing improvement in disability after 5 years of ...
TG Therapeutics Announces FDA Approval of BRIUMVI™ …
Dec 28, 2022 · BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion twice-a-year following the starting dose. U.S. Commercial launch expected Q1 2023. Company to host conference call on Thursday, December 29, 2022 at 8:30 AM ET.
AAN 2024: Briumvi found to ease disability in certain MS patients
Apr 22, 2024 · Two years of treatment with Briumvi (ublituximab) in clinical trials resulted in a confirmed reduction in disability for more than 1 in 10 people with early relapsing multiple sclerosis (MS) who...
Home - TG Therapeutics
BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92
Sep 18, 2024 · These data demonstrate that patients treated with BRIUMVI for up to 5 years had sustained clinical benefit, including further reductions in the risk of relapse in later years of treatment and an impressively low rate of confirmed disability progression.
FDA Approval of Ublituximab, Now Briumvi, Is Good News
Jan 6, 2023 · Shortly after Christmas, the U.S. Food and Drug Administration (FDA) approved Briumvi (ublituximab), which joins a small group of DMTs that aim to halt MS progression by knocking out certain...
Half of US neurologists expect to test Briumvi in the next 6...
Mar 20, 2023 · Most neurologists in the U.S. are aware of the recent approval of Briumvi (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (MS) and about half anticipate testing the...
FDA Approves Briumvi for Relapsing Multiple Sclerosis - Pharmacy Times
Jan 6, 2023 · The FDA has approved ublituximab-xiiy (Briumvi; TG Therapeutics Inc) for the treatment of relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Briumvi Approved for Relapsing Forms of Multiple Sclerosis
Dec 29, 2022 · The Food and Drug Administration (FDA) has approved Briumvi ™ (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome,...
TG Therapeutics Announces Commercial Launch of BRIUMVI™
NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of...